Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
R RoosendaalB M Michel

Abstract

The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. The daily doses (mg/kg) that protected 50% of the animals from death, when calculated for administration at 6 h intervals or by continuous infusion, were as follows: ceftazidime 24.4 and 1.5 (p less than 0.001), gentamicin 2.8 and 3.8 (p greater than 0.05), and ciprofloxacin 3.3 and 6.5 (p less than 0.05), respectively. This correlates with the observation that ceftazidime killed Klebsiella pneumoniae slowly but constantly, and relatively independently of concentration, whereas killing by gentamicin or ciprofloxacin was rapid, and markedly dependent on antibiotic concentration. Exposure of bacteria for 1 h to concentrations of fivefold the MBC did not give rise to a postantibiotic effect for any of the drugs. In our model ceftazidime was far more effective when given continuously than when administered at 6 h intervals. On the other hand, the activity of gentamicin was not influenced by the mode of administration, whereas ciprofloxacin was slightly more effective when given intermittently. However, to avoid misleading conclusions regarding the use of ant...Continue Reading

References

Jul 1, 1978·Antimicrobial Agents and Chemotherapy·M NishidaN Okada
Sep 1, 1979·Reviews of Infectious Diseases·O Zak, F Kradolfer
May 1, 1978·The Journal of Antimicrobial Chemotherapy·N E ReinerW L Thompson
Jun 1, 1977·The Journal of Infectious Diseases·P T FrameT W Bannister
Mar 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A U GerberU Greter
Jul 1, 1985·The Journal of Antimicrobial Chemotherapy·C S Easmon, J P Crane
Dec 1, 1985·European Journal of Clinical Microbiology·A Forsgren, P I Bergkvist
Jun 30, 1986·The American Journal of Medicine·J E Kapusnik, M A Sande
Apr 1, 1987·The Journal of Antimicrobial Chemotherapy·M PechèreJ C Pechère
Dec 1, 1986·The Journal of Antimicrobial Chemotherapy·F BaqueroM F Vicente
Jun 1, 1987·Annals of Internal Medicine·W A Craig, B Vogelman
May 1, 1986·The Journal of Pediatrics·B Vogelman, W A Craig
Oct 1, 1983·European Journal of Clinical Microbiology·D Milatovic
Oct 8, 1982·Biochimica Et Biophysica Acta·E W Thompson, R L Drake
Jan 1, 1981·Reviews of Infectious Diseases·R W BundtzenW A Craig
Jan 1, 1981·Reviews of Infectious Diseases·H C Neu
Jan 1, 1982·Critical Reviews in Microbiology·B A Atkinson, L Amaral
Jan 1, 1981·Reviews of Infectious Diseases·C M Kunin

❮ Previous
Next ❯

Citations

Dec 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R RoosendaalM F Michel
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·W Craig
Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·W Craig
Jul 22, 2006·Intensive Care Medicine·Cassio GirardiUNKNOWN Experimental ICU Study Group
Jun 29, 2013·Clinical Pharmacokinetics·Tiphaine Goulenok, Bruno Fantin
Feb 6, 2004·Best Practice & Research. Clinical Anaesthesiology·Jan Frederik Bugge
Jul 5, 2003·Journal of Microbiological Methods·Irma A J M Bakker-Woudenberg
Jul 10, 2008·International Journal of Antimicrobial Agents·N Belmatoug, B Fantin
Mar 18, 2000·International Journal of Antimicrobial Agents·H Mattie
Jul 4, 2008·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Sep 1, 2007·Current Opinion in Critical Care·Johan W Mouton, Alexander A Vinks
Aug 1, 1991·Antimicrobial Agents and Chemotherapy·O Zak, T O'Reilly
Feb 10, 1996·BMJ : British Medical Journal·M BarzaJ Lau
Jul 4, 2012·Annals of Intensive Care·Bruno Van HerendaelMargareta Ieven
Aug 4, 2006·Clinical Pharmacokinetics·Jason A Roberts, Jeffrey Lipman
Jan 1, 1990·Intensive Care Medicine·I A Bakker-Woudenberg, R Roosendaal
Mar 1, 1991·Antimicrobial Agents and Chemotherapy·D N Gilbert
Jul 6, 2014·Diagnostic Microbiology and Infectious Disease·T W FeltonJ A Roberts
Dec 20, 1999·The Journal of Antimicrobial Chemotherapy·K E BowkerA P MacGowan
Aug 13, 2011·British Journal of Clinical Pharmacology·Jason A RobertsJennifer H Martin
Jun 1, 1990·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·S C Ebert, W A Craig
Jan 28, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Benoît PilmisNajoua El Helali
Oct 3, 1999·Antimicrobial Agents and Chemotherapy·J W MoutonW A Craig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.